Antibacterial Profile of a Microbicidal Agent Targeting Tyrosine Phosphatases and Redox Thiols, Novel Drug Targets.
antimicrobial
drug target
nitroalkenyl benzenes
nitropropenyl benzodioxole
protein tyrosine phosphatase inhibitor
redox signaling
thiol oxidant
tyrosine signaling
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
27 Oct 2021
27 Oct 2021
Historique:
received:
12
09
2021
revised:
23
10
2021
accepted:
24
10
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
The activity profile of a protein tyrosine phosphatase (PTP) inhibitor and redox thiol oxidant, nitropropenyl benzodioxole (NPBD), was investigated across a broad range of bacterial species. In vitro assays assessed inhibitory and lethal activity patterns, the induction of drug variants on long term exposure, the inhibitory interactions of NPBD with antibiotics, and the effect of plasma proteins and redox thiols on activity. A literature review indicates the complexity of PTP and redox signaling and suggests likely metabolic targets. NPBD was broadly bactericidal to pathogens of the skin, respiratory, urogenital and intestinal tracts. It was effective against antibiotic resistant strains and slowly replicating and dormant cells. NPBD did not induce resistant or drug-tolerant phenotypes and showed low cross reactivity with antibiotics in synergy assays. Binding to plasma proteins indicated lowered in-vitro bioavailability and reduction of bactericidal activity in the presence of thiols confirmed the contribution of thiol oxidation and oxidative stress to lethality. This report presents a broad evaluation of the antibacterial effect of PTP inhibition and redox thiol oxidation, illustrates the functional diversity of bacterial PTPs and redox thiols, and supports their consideration as novel targets for antimicrobial drug development. NPBD is a dual mechanism agent with an activity profile which supports consideration of tyrosine phosphatases and bacterial antioxidant systems as promising targets for drug development.
Identifiants
pubmed: 34827248
pii: antibiotics10111310
doi: 10.3390/antibiotics10111310
pmc: PMC8615086
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : RMIT University and BioDiem Ltd
ID : N/A
Références
Clin Pharmacokinet. 2005;44(2):201-10
pubmed: 15656698
J Chem Biol. 2017 Jun 5;10(3):143-150
pubmed: 28685000
Biochem Biophys Res Commun. 2014 Jan 17;443(3):899-904
pubmed: 24361891
Nucleic Acids Res. 2006 Mar 20;34(5):1588-96
pubmed: 16549871
PLoS One. 2018 Jan 2;13(1):e0190402
pubmed: 29293606
Microbiol Mol Biol Rev. 2013 Mar;77(1):1-52
pubmed: 23471616
mBio. 2012 Mar 01;3(1):e00318-11
pubmed: 22354958
Antimicrob Agents Chemother. 2019 Jun 24;63(7):
pubmed: 31036690
J Biol Chem. 2018 Oct 5;293(40):15569-15580
pubmed: 30131335
Antimicrob Agents Chemother. 2011 Jul;55(7):3067-74
pubmed: 21537013
Int J Mol Sci. 2020 Dec 09;21(24):
pubmed: 33317219
J Biochem. 2020 Feb 1;167(2):151-163
pubmed: 31599960
Genome Biol Evol. 2014 Apr;6(4):800-17
pubmed: 24728941
Annu Rev Microbiol. 2015;69:527-47
pubmed: 26359969
Redox Biol. 2019 Jan;20:130-145
pubmed: 30308476
Front Microbiol. 2017 Jan 10;7:2163
pubmed: 28119680
Ann Clin Microbiol Antimicrob. 2014 Sep 12;13:45
pubmed: 25213463
Biochemistry. 2004 Nov 30;43(47):15014-21
pubmed: 15554709
Antimicrob Agents Chemother. 2009 May;53(5):1832-9
pubmed: 19223635
Front Microbiol. 2012 Jul 19;3:261
pubmed: 22833742
FEBS J. 2013 Jan;280(2):346-78
pubmed: 23176256
Genomics Proteomics Bioinformatics. 2011 Oct;9(4-5):119-27
pubmed: 22196355
J Antimicrob Chemother. 2003 Jul;52(1):1
pubmed: 12805255
Science. 2016 Dec 16;354(6318):
pubmed: 27980159
Antimicrob Agents Chemother. 2014 Aug;58(8):4573-82
pubmed: 24867991
Trends Pharmacol Sci. 2017 Jun;38(6):524-540
pubmed: 28412041
J Antimicrob Chemother. 2009 May;63(5):928-36
pubmed: 19240079
FEMS Microbiol Rev. 2016 May;40(3):398-417
pubmed: 26926353
Arch Toxicol. 2016 Jul;90(7):1585-604
pubmed: 27161440
Nat Rev Microbiol. 2017 Aug;15(8):453-464
pubmed: 28529326
Antimicrob Agents Chemother. 2010 Feb;54(2):602-9
pubmed: 19995928
AAPS J. 2009 Mar;11(1):1-12
pubmed: 19117135
Biochem J. 2009 May 13;420(2):155-60
pubmed: 19366344
Mol Microbiol. 2007 Mar;63(6):1797-805
pubmed: 17367396
Front Microbiol. 2014 Oct 22;5:538
pubmed: 25374563
Free Radic Biol Med. 2015 Jul;84:344-354
pubmed: 25819161
Free Radic Biol Med. 2019 Aug 20;140:14-27
pubmed: 31201851
Cell Chem Biol. 2017 Aug 17;24(8):993-1004.e4
pubmed: 28781126
Front Microbiol. 2016 Feb 16;7:184
pubmed: 26909079
FEMS Microbiol Lett. 2020 Mar 1;367(5):
pubmed: 31960902
Antimicrob Agents Chemother. 1985 Nov;28(5):601-6
pubmed: 4091525
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4433-41
pubmed: 27246781
Microorganisms. 2016 Feb 16;4(1):
pubmed: 27681908
Mol Biosyst. 2017 Jun 27;13(7):1257-1279
pubmed: 28534914
SLAS Discov. 2017 Oct;22(9):1071-1083
pubmed: 28745976
Open Med Chem J. 2014 May 30;8:1-16
pubmed: 24976873
Gene. 2019 Sep 10;713:143951
pubmed: 31269464
Clin Microbiol Rev. 2000 Oct;13(4):534-46
pubmed: 11023955
Curr Top Med Chem. 2017;17(1):4-15
pubmed: 27449257
J Bacteriol. 2005 Jul;187(14):4945-56
pubmed: 15995210
Mol Microbiol. 2015 Sep;97(6):1195-208
pubmed: 26094643
Expert Opin Pharmacother. 2015 Feb;16(2):151-3
pubmed: 25483564
J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
pubmed: 2359136
Biochimie. 2019 Oct;165:156-160
pubmed: 31377193
Klin Lab Diagn. 2003 Jul;(7):50-2
pubmed: 12934337
Appl Microbiol Biotechnol. 2017 May;101(10):3977-3989
pubmed: 28409380
J Clin Microbiol. 2011 Jul;49(7):2680-4
pubmed: 21525224
Sci Total Environ. 2020 May 10;716:137062
pubmed: 32036144
Enzyme Res. 2011;2011:794089
pubmed: 22195276
Cell Rep. 2015 Nov 3;13(5):968-80
pubmed: 26565910